Manufacturer
Bayer Korea Ltd
Contents
Enrofloxacin 50mg/ml with 30mg n-butyl alcohol
Indication
1) Dogs and Cats: treats bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
2) Cattle: treats diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and secondary bacterial infections subsequent to viral conditions (e.g. viral pneumonia) where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
3) Pigs: treats diseases of the respiratory and alimentary tract of bacterial or mycoplasmal origin (e.g. pasteurellosis, actinobacillosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and salmonellosis) and mulifactorial diseases such as atrophic rhinitis and enzootic pneumonia, where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.
Instruction
1) Dogs and Cats: 5mg enrofloxacin per kg bodyweight (1.0 ml/10 kg) daily by subcutaneous injection once daily for up to 5 days. Treatment may be initiated with the product and maintained with Baytril Flavour Tablets.
2) Cattle: 2.5 mg enrofloxacin per kg bodyweight (0.5 ml/10 kg) daily by subcutaneous injection for 3 days. This rate may be doubled to 5 mg enrofloxacin per kg bodyweight (1.0 ml/10 kg) for 5 days for salmonellosis and complicated respiratory diseases. Not more than 10 ml should be administered at the one subcutaneous injection site.
3) Pigs: 2.5 mg enrofloxacin per kg bodyweight (0.5 ml/10 kg) daily by intramuscular injection for 3 days. This rate may be doubled to 5 mg enrofloxacin per kg bodyweight (1.0 ml/10 kg) for 5 days for salmonellosis and complicated respiratory diseases. Not more than 2.5 ml should be administered at the one intramuscular site.
Drug interaction
No information.
Malaysia
